BERGEN, Norway, Nov. 13, 2024 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half […]
Tag: BerGenBio ASA
BerGenBio Third Quarter Results 2024
BERGEN, Norway, Nov. 13, 2024 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half […]
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
Ph1b data support safety, predictable PK and adequate plasma exposure BERGEN, Norway, Oct. 7, 2024 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, […]
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
Ph1b data support safety, predictable PK and adequate plasma exposure BERGEN, Norway, Oct. 7, 2024 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, […]
Solid clinical and financial progress
BERGEN, Norway, Aug. 21, 2024 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half […]
